January 13, 2015
Daiichi Sankyo announced on January 9 that the US FDA has approved its anticoagulant edoxaban (US brand name: Savaysa). The product is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) and...read more